Spanish 
English 
COVID-19 Testing Strategy Simulator
There are many strategies that will reduce infection in your population. Any testing will reduce your disease burden. Using this tool to compare pooling, test accuracy, testing frequency, and costs will allow you to choose the strategy best suited to your needs and your community.
March 3, 2021
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts | Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial | Sequelae in Adults at 6 Months After COVID-19 Infection
February 22, 2021
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study | Multisystem Inflammatory Syndrome in Children (MIS-C) | Decreased SARS-CoV-2 viral load following vaccination
February 8, 2021
Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients | Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization | Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2
February 1, 2021
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial | Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial | SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
January 25, 2021
COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings | The impact of Spike mutations on SARS-CoV-2 neutralization | Vitamin D Status is Associated With In-hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients
January 18, 2021
SARS-CoV-2 encephalitis is a cytokine release syndrome: evidence from cerebrospinal fluid analyses | Evolution of antibody immunity to SARS-CoV-2 | Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
- « Anterior
- 1
- 2
- 3
- 4
- …
- 10
- Siguiente »
Situation Dashboards
World Health Organization (WHO)
Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)
Johns Hopkins University (JHU)
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU
COVID-19 in US and Canada
1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources
Genomic Epidemiology COVID-19
Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.
